Shijiazhuang Yiling Valuation Multiples

Shijiazhuang Yiling Overview

About Shijiazhuang Yiling

Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company that engages in pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumors, diabetes, and related complications. Its products include drug series, chemical drugs, Chinese medicine series, and health products.

Founded

2001

HQ

Employees

11.7K

Website

yiling.cn

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $1B

EBITDA: $309M

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Shijiazhuang Yiling Financials

Shijiazhuang Yiling reported last 12-month revenue of $1B and EBITDA of $309M.

In the same LTM period, Shijiazhuang Yiling generated $674M in gross profit, $309M in EBITDA, and $187M in net income.

Shijiazhuang Yiling P&L

In the most recent fiscal year, Shijiazhuang Yiling reported revenue of $955M and EBITDA of ($23M).

Shijiazhuang Yiling expects next 12-month revenue of XXX and NTM EBITDA of XXX

Shijiazhuang Yiling Stock Performance

Shijiazhuang Yiling has current market cap of $4B, and enterprise value of $4B.

Shijiazhuang Yiling's stock price is $2.45.

Shijiazhuang Yiling Valuation Multiples

Shijiazhuang Yiling trades at 3.1x EV/Revenue multiple, and 12.3x EV/EBITDA.

Shijiazhuang Yiling Financial Valuation Multiples

As of April 18, 2026, Shijiazhuang Yiling has market cap of $4B and EV of $4B.

Equity research analysts estimate Shijiazhuang Yiling's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Shijiazhuang Yiling has a P/E ratio of 21.9x.

Shijiazhuang Yiling Margins & Growth Rates

Shijiazhuang Yiling's revenue in the last 12 month grew by 12%.

Shijiazhuang Yiling's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.

Shijiazhuang Yiling's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Shijiazhuang Yiling's rule of X is 55% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Shijiazhuang Yiling Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Shijiazhuang Yiling M&A Activity

Shijiazhuang Yiling acquired XXX companies to date.

Last acquisition by Shijiazhuang Yiling was on XXXXXXXX, XXXXX. Shijiazhuang Yiling acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Shijiazhuang Yiling Investment Activity

Shijiazhuang Yiling invested in XXX companies to date.

Shijiazhuang Yiling made its latest investment on XXXXXXXX, XXXXX. Shijiazhuang Yiling invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).